Abstract
Purpose
The available literature on the treatment options for recurrent or metastatic endometrial cancer (EC) is full of controversies. Therefore, we explore the results of the AGO pattern of care studies from the years 2013, 2009 and 2006.
Methods
A questionnaire was developed and sent to all 682 German gynecological departments in 2013 (775 in 2009, 500 in 2006, respectively). The results of the questionnaires were compared with each other using Fisher’s exact test.
Results
Responses were available in 40.0 % in 2013, 33.3 % in 2009 and 35.8 % in 2006. In 2013 the most preferred endocrine drug was progestin (79.8 %), followed by tamoxifen (42.8 %), aromatase inhibitor (19.8 %), fulvestrant (16.3 %) and a combination (3.9 %) (p < 0.001). 65.3, 59.8, 51.7 and 38.2 % of the participants used platinum, taxane, a combination of cytostatic drugs, anthracycline in metastatic EC, respectively (p = 0.215). 96.2, 92.7, 49.8 and 60.9 % of the participants performed an operation, radiotherapy, endocrine therapy and chemotherapy in 2013 because of a local recurrence, respectively (p < 0.001). Compared to 2009 and 2006 these rates remained stable (no p value <0.05). Because of a distant metastasis 50.4, 64.2, 78.5 and 90.8 % of the participants performed an operation, radiotherapy, endocrine therapy and chemotherapy in 2013, respectively (p < 0.001). Compared to 2009 and 2006 more participants performed an operation or radiotherapy and less an endocrine treatment.
Conclusions
Whereas progestin was the favorite drug, the participants of this study did not prefer a specific cytostatic drug for metastatic EC in 2013. This might have reflected the available literature, which did not provide a real standard of care.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gebärmutterkörper (2010) Krebs in Deutschland 80–83. Accessed at http://www.rki.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2013/kid_2013_c54-55_gebaermutterkoerper.pdf;jsessionid=D687D7570E564374CAB3C53CCABF8F0E.2_cid390?__blob=publicationFile
Creutzberg CL, van Putten WLJ, Koper P et al (2003) Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 89:201–209
Fleisch MC, Pantke P, Beckmann MW et al (2007) Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol 95:476–484
Westin SN, Rallapalli V, Fellman B et al (2014) Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol 134:546–551
Temkin SM, Fleming G (2009) Current treatment of metastatic endometrial cancer. Cancer Control 16:38–45
Humber CE, Tierney J, Symonds R (2007) Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 18:409–420
Sommeijer DW, Sjoquist KM, Friedlander M (2013) Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature. Curr Oncol Reports 15:541–548
Bradford LS, Rauh-Hain JA, Schorge J et al (2013) Advances in the management of recurrent endometrial cancer. Am J Clin Oncol, PMID 23764681
Battista MJ, Schmidt M, Rieks N et al (2014) Nationwide analysis on surgical procedures for patients with endometrial cancer in Germany: Results of the AGO pattern of care studies from the years 2013, 2009, and 2006. J Canc Res Clin Oncol 140:2087–2093
Battista MJ, Schmidt M, Rieks N et al (2015) Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009, and 2006. J Canc Res Clin Oncol 141:555–562
Battista MJ, Steiner E, Rieks N et al (2013) Nationwide analysis on surgical staging procedures and systemic treatment for patients with endometrial cancer in Germany. Int J Gynecol Canc 23:105–112
Fiorica JV, Brunetto V, Hanjani P et al (2004) Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:10–14
Whitney C, Brunetto V, Zaino R et al (2004) Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:4–9
Rose PG, Brunetto V, VanLe L et al (2000) A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78:212–216
Thigpen BT, Brady MF, Homesley HD et al (2001) Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 19:364–367
Ma B, Oza A, Eisenhauer E et al (2004) The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers–a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Canc 14:650–658
Emons G, Günthert A, Thiel F et al (2013) Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie. Gynecol Oncol 129:495–499
Lissoni A, Zanetta G, Losa G et al (1996) Phase II study of paclitaxel as salvage treatment in advancer endometrial cancer. Ann Oncol 13:861–863
Ball HG, Blessing JA, Lentz SS et al (1996) Phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 281:278–281
Lincoln S, Blessing JA, Lee RB et al (2003) Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 88:277–281
Hirai Y, Hasumi K, Onose R et al (2004) Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group. Gynecol Oncol 94:471–476
Obel J, Friberg G, Fleming G (2006) Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol 6:459–468
Fleming GF, Brunetto V, Cella D et al (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22:2159–2166
Miller D, Filiaci V, Fleming G et al (2012) Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125:771
Conflict of interest
The authors declare that they have no conflicts of interests and signed the conflict of interest form.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Battista, M.J., Schmidt, M., Eichbaum, M. et al. Management of recurrent or metastatic endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. Arch Gynecol Obstet 292, 1355–1360 (2015). https://doi.org/10.1007/s00404-015-3786-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-015-3786-y